A. Aggarwal, R. Agarwal, S. Dhooria, K. Prasad, I. Sehgal, V. Muthu
{"title":"发展中国家2019年慢性呼吸道疾病和冠状病毒病:系统综述","authors":"A. Aggarwal, R. Agarwal, S. Dhooria, K. Prasad, I. Sehgal, V. Muthu","doi":"10.4103/jncd.jncd_5_22","DOIUrl":null,"url":null,"abstract":"The proportion of coronavirus disease 2019 (COVID-19) patients having a chronic respiratory disease (CRD), and its impact on COVID-19 related patient outcomes, is unclear. We conducted this systematic review to evaluate the proportion of patients with asthma or chronic obstructive pulmonary disease (COPD) among COVID-19 patients, and to assess if comorbid CRD worsens COVID-19 outcomes, in developing countries. We queried PubMed database for studies conducted in developing countries and provided data on the proportion of COVID-19 patients with CRD, or severe disease or mortality among COVID-19 patients with and without CRD. We calculated proportion of CRD patients and relative risk (RR) for each reported outcome of interest. We used random-effects models to summarize our data. We retrieved 1947 citations and included 22 studies from developing countries in our review. The pooled estimate for proportion of asthma and COPD was 2.32% (95% confidence interval [CI] 1.86%–2.83%) and 3.52% (95% CI 2.14%–5.20%), respectively. COVID-19 patients with asthma had a higher risk of severe COVID-19 (summary RR 1.21, 95% CI 1.17–1.25), but not of mortality (summary RR 1.01, 95% CI 0.80–1.28), as compared to COVID-19 patients without asthma. COVID-19 patients with COPD had a higher risk of severe COVID-19 (summary RR 1.48, 95% CI 1.30–1.69) and mortality (summary RR 2.69, 95% CI 1.57–4.61), as compared to COVID-19 patients without COPD. Patients with asthma (but not COPD) in developing countries may be less likely to acquire COVID-19. Both diseases may increase the risk of severe COVID-19, and COPD may increase risk of COVID-19-related mortality.","PeriodicalId":52935,"journal":{"name":"International Journal of Noncommunicable Diseases","volume":null,"pages":null},"PeriodicalIF":0.2000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Chronic respiratory disease and coronavirus disease 2019 in developing countries: A systematic review\",\"authors\":\"A. Aggarwal, R. Agarwal, S. Dhooria, K. Prasad, I. Sehgal, V. Muthu\",\"doi\":\"10.4103/jncd.jncd_5_22\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The proportion of coronavirus disease 2019 (COVID-19) patients having a chronic respiratory disease (CRD), and its impact on COVID-19 related patient outcomes, is unclear. We conducted this systematic review to evaluate the proportion of patients with asthma or chronic obstructive pulmonary disease (COPD) among COVID-19 patients, and to assess if comorbid CRD worsens COVID-19 outcomes, in developing countries. We queried PubMed database for studies conducted in developing countries and provided data on the proportion of COVID-19 patients with CRD, or severe disease or mortality among COVID-19 patients with and without CRD. We calculated proportion of CRD patients and relative risk (RR) for each reported outcome of interest. We used random-effects models to summarize our data. We retrieved 1947 citations and included 22 studies from developing countries in our review. The pooled estimate for proportion of asthma and COPD was 2.32% (95% confidence interval [CI] 1.86%–2.83%) and 3.52% (95% CI 2.14%–5.20%), respectively. COVID-19 patients with asthma had a higher risk of severe COVID-19 (summary RR 1.21, 95% CI 1.17–1.25), but not of mortality (summary RR 1.01, 95% CI 0.80–1.28), as compared to COVID-19 patients without asthma. COVID-19 patients with COPD had a higher risk of severe COVID-19 (summary RR 1.48, 95% CI 1.30–1.69) and mortality (summary RR 2.69, 95% CI 1.57–4.61), as compared to COVID-19 patients without COPD. Patients with asthma (but not COPD) in developing countries may be less likely to acquire COVID-19. Both diseases may increase the risk of severe COVID-19, and COPD may increase risk of COVID-19-related mortality.\",\"PeriodicalId\":52935,\"journal\":{\"name\":\"International Journal of Noncommunicable Diseases\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Noncommunicable Diseases\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/jncd.jncd_5_22\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Noncommunicable Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jncd.jncd_5_22","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
摘要
目前尚不清楚2019冠状病毒病(COVID-19)患者患有慢性呼吸道疾病(CRD)的比例及其对COVID-19相关患者结局的影响。我们进行了这项系统综述,以评估发展中国家的COVID-19患者中哮喘或慢性阻塞性肺疾病(COPD)患者的比例,并评估合并症CRD是否会恶化COVID-19的结局。我们查询了PubMed数据库中在发展中国家进行的研究,并提供了COVID-19患者中发生CRD的比例,或伴有和不伴有CRD的COVID-19患者中严重疾病或死亡率的数据。我们计算了每个报告结果的CRD患者比例和相对风险(RR)。我们使用随机效应模型来总结我们的数据。我们检索了1947条引文,并在我们的综述中纳入了22项来自发展中国家的研究。哮喘和COPD的合并估计比例分别为2.32%(95%可信区间[CI] 1.86%-2.83%)和3.52% (95% CI 2.14%-5.20%)。与没有哮喘的COVID-19患者相比,合并哮喘的COVID-19患者发生严重COVID-19的风险更高(总RR为1.21,95% CI为1.17-1.25),但死亡率不高(总RR为1.01,95% CI为0.80-1.28)。与没有COPD的COVID-19患者相比,合并COPD的COVID-19患者发生严重COVID-19(总RR为1.48,95% CI为1.30-1.69)和死亡率(总RR为2.69,95% CI为1.57-4.61)的风险更高。发展中国家的哮喘(但不包括慢性阻塞性肺病)患者可能不太可能感染COVID-19。这两种疾病都可能增加严重COVID-19的风险,而慢性阻塞性肺病可能增加COVID-19相关死亡的风险。
Chronic respiratory disease and coronavirus disease 2019 in developing countries: A systematic review
The proportion of coronavirus disease 2019 (COVID-19) patients having a chronic respiratory disease (CRD), and its impact on COVID-19 related patient outcomes, is unclear. We conducted this systematic review to evaluate the proportion of patients with asthma or chronic obstructive pulmonary disease (COPD) among COVID-19 patients, and to assess if comorbid CRD worsens COVID-19 outcomes, in developing countries. We queried PubMed database for studies conducted in developing countries and provided data on the proportion of COVID-19 patients with CRD, or severe disease or mortality among COVID-19 patients with and without CRD. We calculated proportion of CRD patients and relative risk (RR) for each reported outcome of interest. We used random-effects models to summarize our data. We retrieved 1947 citations and included 22 studies from developing countries in our review. The pooled estimate for proportion of asthma and COPD was 2.32% (95% confidence interval [CI] 1.86%–2.83%) and 3.52% (95% CI 2.14%–5.20%), respectively. COVID-19 patients with asthma had a higher risk of severe COVID-19 (summary RR 1.21, 95% CI 1.17–1.25), but not of mortality (summary RR 1.01, 95% CI 0.80–1.28), as compared to COVID-19 patients without asthma. COVID-19 patients with COPD had a higher risk of severe COVID-19 (summary RR 1.48, 95% CI 1.30–1.69) and mortality (summary RR 2.69, 95% CI 1.57–4.61), as compared to COVID-19 patients without COPD. Patients with asthma (but not COPD) in developing countries may be less likely to acquire COVID-19. Both diseases may increase the risk of severe COVID-19, and COPD may increase risk of COVID-19-related mortality.